US FDA withdraws approval of Covis Pharma's preterm birth prevention drug

April 07, 2023 12:10 AM AEST | By Reuters
Follow us on Google News:

April 6 (Reuters) - The U.S. Food and Drug Administration (FDA) on Thursday withdrew its approval of Covis Pharma's Makena drug for preventing preterm birth due to lack of effectiveness, several years after the drug received clearance. (Reporting by Khushi Mandowara in Bengaluru; Editing by Rashmi Aich)


The above content is directly sourced from Reuters under a contractual arrangement. The content is being provided as a convenience and for informational purposes only; and does not constitute an endorsement or approval by Kalkine Media of any of the products, services, or opinions of the organization or individual. The user is apprised that Kalkine Media bears no responsibility for the accuracy, legality, or content of Reuters, any external sites, or for that of subsequent links. The user is requested to contact Reuters directly for answers to questions regarding the content. Please note that Kalkine Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Top ASX Listed Companies

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK